Preview Mode Links will not work in preview mode

Oct 28, 2019

Breast Cancer Update, Issue 3, 2019 — Part 1: Our interview with Dr Goetz highlights the following topics as well as cases from his practice:

  • Case: A woman in her mid-30s with de novo ER-positive, HER2-negative metastatic breast cancer (mBC) achieves a complete clinical response to palbociclib, letrozole and ovarian suppression (00:00)
  • Importance of providing support to patients and their families coping with a diagnosis of mBC (01:15)
  • Therapeutic options for patients with de novo ER-positive, HER2-negative mBC (03:45)
  • Activity and tolerability of gonadotropin-releasing hormone agonists (05:35)
  • Selection of patients for treatment with CDK4/6 inhibitors in combination with endocrine therapy (09:07)
  • Mechanism of action of CDK4/6 inhibitors (12:13)
  • Role of everolimus and alpelisib in the management of ER-positive mBC (14:30)
  • Implications of ESR1 mutations for the management of ER-positive mBC; use of selective estrogen receptor degraders (SERDs) (16:15)
  • Activity of the selective estrogen receptor modulators endoxifen and lasofoxifene for mBC with ESR1 mutation (19:48)
  • Tolerability profiles of the CDK4/6 inhibitors palbociclib, ribociclib and abemaciclib; dose reduction to mitigate side effects (21:21)
  • CNS penetration of abemaciclib; management of abemaciclib-associated diarrhea (25:26)
  • Effects of site and extent of metastases on outcomes with CDK4/6 inhibitors (27:02)
  • Efficacy of CDK4/6 inhibitors in combination with endocrine therapy for ER-positive mBC (29:29)
  • Survival outcomes with CDK4/6 inhibitors and endocrine therapy for ER-positive mBC (31:28)
  • Response to palbociclib and endocrine therapy in patients with ER-positive mBC (34:17)
  • Selection of therapy for patients with locally advanced ER-positive, HER2-negative breast cancer (36:41)
  • Therapeutic approach for patients who experience disease progression on a CDK4/6 inhibitor (39:33)
  • Activity of alpelisib for ER-positive advanced breast cancer with a PIK3CA mutation (47:02)
  • Side-effect profile of alpelisib (49:41)
  • Case: A woman in her late 60s with high-grade, ER-positive, HER2-negative breast cancer and a 21-gene assay Recurrence Score (RS) of 52 receives adjuvant chemotherapy (52:54)
  • Role of bone-modifying agents for patients with ER-positive breast cancer and bone metastases (58:04)
  • Ongoing investigations of CDK4/6 inhibitors in the adjuvant setting (59:40)
  • Effects of CDK4/6 inhibitors on immunity; potential for combination with immune checkpoint inhibitors (1:01:14)
  • TAILORx trial: Adjuvant chemotherapy guided by a 21-gene expression assay for women with ER-positive, HER2-negative, node-negative breast cancer (1:06:19)
  • Impact of clinical risk on prognosis and prediction of chemotherapy benefit by age and RS in the TAILORx study for patients with early breast cancer (1:07:46)
  • Perspective on the use of gene expression assays to determine risk of recurrence and guide adjuvant decision-making (1:14:30)
  • Cancer cell dormancy and risk of late recurrence (1:16:47)

CME information and select publications